FDA Import Refusal 1FX-7544854-7/10002/1A — CAPLINT POINT
The FDA refused shipment 1FX-7544854-7/10002/1A from CAPLINT POINT (Guatemala) on May 29, 2026. The refused product falls under Drugs and Biologics — NAPROXEN (ANTI-INFLAMMATORY). Cited charges: 472,75
Refusal Details
- Date
- May 29, 2026
- Country
- Guatemala
- Product Category
- Drugs and Biologics
- Product Code
- 62GDA49 NAPROXEN (ANTI-INFLAMMATORY)
- Charges
- 472,75